Targeted inhibition of NLRP3 inflammasome activation attenuates alpha-synuclein-driven microglial neuroinflammation, reduces IL-1β/IL-18-mediated dopaminergic neuron loss, and may slow PD progression. Oral CNS-penetrant inhibitors (dapansutrile, NT-0796) have entered Phase 2 trials, representing the most translationally viable anti-inflammatory approach in neurodegeneration.
No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF male C57BL/6 mice receive oraldapansutrile (30 mg/kg/day) beginning 4 weeks after intrastriatal alpha-synuclein preformed fibril injection (a model of prodromal PD), THEN striatal IL-1β concentrati | Striatal IL-1β concentration reduced by ≥40%; nigral TH+ neuron survival improved by ≥30% versus vehicle controls | — no observation — | pending | 0.55 |
| IF patients with early-stage Parkinson's disease (Hoehn-Yahr stage 1-2) receive oral NT-0796 (200 mg BID) for 52 weeks, THEN their 123I-FP-CIT (DaTscan) binding decline will be ≤30% from baseline comp | DaTscan SPECT binding (putaminal specific binding ratio) decline ≤30% from baseline at week 52 in the active group | — no observation — | pending | 0.35 |